Filtered By:
Condition: Hypertension
Drug: Hydroxychloroquine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 11 results found since Jan 2013.

Hydroxychloroquine exposure reduces the risk of cardiovasular disease events in patients with hypertension or diabetes mellitus
CONCLUSIONS: HCQ has protective effect on CVD events, including both AMI and ischaemic stroke in the patients with traditional risk factors. The protective effect of HCQ on CVD events is prominent in older patients.PMID:37246776 | DOI:10.55563/clinexprheumatol/y7psev
Source: Clinical and Experimental Rheumatology - May 29, 2023 Category: Rheumatology Authors: Chun-Hsiung Chen Hung-An Chen Hsien-Tzung Liao Chen-Hung Chen Source Type: research

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - September 22, 2020 Category: Drugs & Pharmacology Authors: Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD Tags: Acta Pharmacol Sin Source Type: research

Torsades de Pointes in Coronavirus Disease 2019 Infection
A 73-YEAR-OLD MAN (weight 69 kg, height 175 cm) was transferred to the authors ’ critical care unit with respiratory and acute renal failure secondary to coronavirus disease 2019 (COVID-19) infection. His past medical history included hypertension, diabetes, and previous stroke, from which he had made a full recovery. The patient was treated with mechanical ventilation and p eritoneal dialysis. He was recruited into the hydroxychloroquine arm of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial.
Source: Journal of Cardiothoracic and Vascular Anesthesia - July 31, 2020 Category: Anesthesiology Authors: Bagrat Lalabekyan, Gudrun Kunst, Vanessa A. Skelton Tags: Diagnostic Dilemma Source Type: research

Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research

Childhood-onset systemic polyarteritis nodosa and systemic lupus erythematosus: an overlap syndrome?
In conclusion, we described herein a possible overlap syndrome of two autoimmune diseases, where childhood-onset systemic polyarteritis nodosa occurred five years before the childhood-onset systemic lupus erythematosus diagnosis.
Source: Revista Brasileira de Reumatologia - July 13, 2015 Category: Rheumatology Source Type: research